Le Lézard
Classified in: Health
Subject: SVY

Cardiovascular Monitoring Devices - Medical Devices Pipeline Assessment, 2017



LONDON, Oct. 6, 2017 /PRNewswire/ -- Summary



Download the full report: https://www.reportbuyer.com/product/3599276


GlobalData's Medical Devices sector report, "Cardiovascular Monitoring Devices - Medical Devices Pipeline Assessment, 2017" provides an overview of Cardiovascular Monitoring Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cardiovascular Monitoring Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
- Extensive coverage of the Cardiovascular Monitoring Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Cardiovascular Monitoring Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Cardiovascular Monitoring Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date

Download the full report: https://www.reportbuyer.com/product/3599276

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
https://www.reportbuyer.com  

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer


These press releases may also interest you

at 00:32
Top 6 Digital Enterprises, a Pennsylvania-based digital arbitrage shop, focuses on delivering high-quality leads to online advertisers. Through forward-thinking strategies, Top6Digital is able to acquire highly motivated customers at below-market...

at 00:00
DALLAS, Apr. 20, 2018 /PRNewswire-PRWeb/ -- Dallas rhinoplasty specialist and meeting chairman, Dr. Rod J. Rohrich, recently hosted the 35th annual Dallas Rhinoplasty Meeting at the Westin Galleria in Dallas, Texas. The two day event, which is...

19 avr 2018
NY State Senator Michael Gianaris (D-12) joined Goodwill Industries of Greater New York and Northern NJ, Inc. (Goodwill NYNJ) to celebrate the talents and career accomplishments of more than 60 individuals with autism who have secured competitive...

19 avr 2018
U.S. District Judge Kristine G. Baker for the Eastern District of Arkansas entered a consent decree of permanent injunction today between the U.S. and Cantrell Drug Company of Little Rock, Arkansas, and the company's Chief Executive Officer and...

19 avr 2018
ESSA Pharma Inc. ("ESSA" or the "Company") , a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that on April 18, 2018 the board of directors of the Company...

19 avr 2018
Rigel Pharmaceuticals, Inc. today announced the pricing of its previously announced underwritten public offering of 16,000,000 shares of its common stock, offered at a price of $3.90 per share to the public.  The gross proceeds to Rigel from this...




News published on 6 october 2017 at 10:12 and distributed by: